Sorrento Therapeutics, Inc. And IGDRASOL Announce The Acquisition Of Exclusive Distribution Rights To Cynviloq™

financial news

"...Cynviloq™ is a next-generation, branded, micellar diblock copolymeric paclitaxel formulation currently approved and marketed in several countries, including South Korea for Metastatic Breast Cancer (MBC), Non-small cell lung cancer (NSCLC) and ovarian cancer. It has also completed Phase 2 studies for potential advancement into registration trials in the U.S. Preliminary data analysis from an ongoing MBC Phase 3 trial in South Korea has indicated a significantly improved overall response rate (ORR) for Cynviloq™ as compared to a solvent-based paclitaxel, a generic version of Taxol®. More comprehensive data analyses will be presented at future medical conferences.....